Ocrelizumab Global Buyers List: Comprehensive Guide to Market Players and Procurement

Ocrelizumab, marketed under the brand name Ocrevus, represents one of the most significant advancements in multiple sclerosis (MS) treatment over the past decade. As a humanized monoclonal antibody targeting CD20-positive B cells, this therapy has transformed disease management for both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). With the global Ocrelizumab market projected to grow from approximately US$965 million in 2025 to over US$3.37 billion by 2032—a compound annual growth rate exceeding 15%—understanding the landscape of global buyers, importers, and distributors has become essential for pharmaceutical companies, contract manufacturers, and healthcare procurement professionals alike.

This comprehensive guide explores the Ocrelizumab global buyers list, examining key market participants, regional dynamics, procurement channels, and strategic considerations for stakeholders across the pharmaceutical supply chain.

Understanding Ocrelizumab: A Market Overview

What Is Ocrelizumab?

Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-expressing B cells. By depleting these cells from peripheral circulation through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity, the therapy reduces immune system attacks on the central nervous system, thereby slowing disease progression and reducing relapse rates .

First approved by the U.S. FDA on March 28, 2017, Ocrelizumab holds the distinction of being the first and only therapy approved for primary progressive MS, addressing a patient population that previously had no disease-modifying treatment options. The drug is administered via intravenous injection, typically once every six months, significantly improving patient compliance compared to more frequent dosing regimens.

Market Size and Growth Trajectory

The commercial success of Ocrelizumab is reflected in its impressive revenue generation. In 2024, the molecule generated CHF 6.7 billion in revenue (approximately $7.5 billion), making Ocrevus one of Roche’s largest pharmaceutical franchises and the undisputed global leader in the anti-CD20 MS market.

According to industry forecasts, the global Ocrelizumab market is expected to expand from US$965 million in 2025 to US$3,378 million by 2032, representing a CAGR of 15.6%. This growth is driven by increasing early diagnosis rates of MS, expanding treatment access in developing regions, and the anticipated approval of subcutaneous formulations that further enhance patient convenience .

The Ocrelizumab Global Buyers List: Key Categories of Purchasers

Understanding the Ocrelizumab buyer ecosystem requires categorizing purchasers by their role in the pharmaceutical supply chain. While a comprehensive, publicly available “Ocrelizumab buyers list” with individual company names is proprietary to trade data platforms, the key buyer categories can be identified and analyzed.

1. Pharmaceutical Manufacturers and License Holders

Primary Manufacturers:

Genentech (Roche Group): As the originator and primary manufacturer of Ocrevus, Genentech holds the dominant position in Ocrelizumab production. The company manufactures the drug in the United States and Europe under strict regulatory standards.
F. Hoffmann-La Roche Ltd.: The Swiss-based parent company oversees global commercialization and distribution through its extensive network of regional subsidiaries .
Chugai Pharmaceutical Co. Ltd.: A Roche affiliate that manages Ocrelizumab distribution in select Asian markets.

Biosimilar Developers and Licensees:
The Ocrelizumab market is witnessing increasing biosimilar activity, which expands the buyer and supplier landscape:

Teva Pharmaceutical Industries and Polpharma Biologics have entered a global licensing agreement granting Teva exclusive worldwide commercialization rights to a proposed Ocrelizumab biosimilar, upon regulatory approval. Polpharma Biologics retains full responsibility for developing and manufacturing the biosimilar candidate.
Amgen has a Phase 3 clinical trial underway for an Ocrelizumab biosimilar.
Biocad and Sandoz are also conducting Phase 3 trials for Ocrelizumab biosimilars.
CinnaGen, an Iranian company, is developing an Ocrelizumab biosimilar for multiple sclerosis.

2. Hospital and Healthcare System Buyers

Hospitals and healthcare systems represent the end-user purchasers of Ocrelizumab for patient administration. These buyers typically procure through:

Hospital Pharmacies: The primary distribution channel for Ocrelizumab, responsible for stocking and dispensing the medication for inpatient and outpatient administration.
Integrated Healthcare Networks: Large hospital groups and health systems that centralize pharmaceutical procurement to achieve economies of scale.

Public procurement data reveals active hospital purchasing across multiple countries. For example, a Ukrainian hospital procurement contract documented the purchase of Ocrelizumab 300 mg/10 mL vials, with delivery to Vinnytsia Regional Clinical Psychoneurological Hospital. Similarly, Brazilian government procurement records show Ocrelizumab acquisition by municipal health departments.

3. Specialty Pharmacies and Wholesale Distributors

Specialty pharmacies and wholesale distributors play a crucial intermediary role in the Ocrelizumab supply chain:

DSCSA-Compliant US Specialty Wholesalers: These distributors source Ocrelizumab from manufacturer-direct channels with full serial traceability, ensuring supply chain integrity.
International Pharma Wholesalers: Companies like Pharmastatus.net specialize in international pharmaceutical wholesale, facilitating cross-border Ocrelizumab procurement even during supply shortages.
Cross-Border Sourcing Platforms: Services like Reserve Meds coordinate with US-licensed specialty wholesale partners to enable named-patient imports on a case-by-case basis.

4. Government and Public Sector Procurement Agencies

Government health agencies and public procurement bodies represent a significant buyer category, particularly in countries with universal healthcare systems. Public tenders and contracts provide visibility into this buyer segment:

Brazil: Multiple government procurement records show Ocrelizumab acquisition by municipal health departments, with unit prices documented in Brazilian Real.
Ukraine: Public procurement platforms like Zakupivli.pro list Ocrelizumab tenders with detailed contract information.
Paraguay: The Ministry of Public Health and Social Welfare (MSPBS) has awarded contracts for Ocrelizumab 300 mg procurement.
Iraq: Government pharmaceutical procurement databases list Ocrelizumab 300 mg/10 mL vials with supplier information.

5. Private Sector Importers and Distributors

Private pharmaceutical importers and distributors complete the buyer ecosystem:

Regional Distributors: Companies that hold import licenses and distribution rights for specific countries or regions. For example, Roche Diagnostics India Pvt. Ltd. markets Ocrelizumab in India.
Bulk API Purchasers: Pharmaceutical companies and contract manufacturers that purchase Ocrelizumab API (active pharmaceutical ingredient) for formulation and commercial manufacturing.
Trade Data Example: Trade data reveals a Turkish buyer, Roce Meeters Industry A, that imported Ocrelizumab 300 mg vials, with trading partners in Germany, the United States, Ireland, and Switzerland.

Regional Distribution of Ocrelizumab Buyers

North America

United States: As the largest pharmaceutical market globally, the United States represents the primary Ocrelizumab market. Buyers include major hospital systems, specialty pharmacies, and the Veterans Health Administration. The DSCSA regulatory framework governs pharmaceutical supply chain integrity.

Canada: Ocrelizumab is approved for use on the Canadian market, with procurement through provincial health systems and hospital pharmacies.

Europe

The European market is characterized by a mix of public healthcare procurement and private distribution:

Germany: A major trading partner for Ocrelizumab imports, as evidenced by trade data.
Switzerland: Home to F. Hoffmann-La Roche Ltd., serving as both manufacturer and distribution hub.
United Kingdom: Ocrelizumab is approved via the EMA, with NHS procurement through hospital pharmacies.
Eastern Europe: Countries like Ukraine demonstrate active public procurement through government tenders.

Asia-Pacific

Japan: Chugai Pharmaceutical manages Ocrelizumab distribution in the Japanese market.
India: Roche Products (India) Pvt. Ltd. introduced Ocrevus in the Indian market in 2024.
China: The Ocrelizumab market is expanding, with growing demand for effective MS treatments.

Latin America

Brazil: Active government procurement through municipal health departments.
Paraguay: Ministry of Public Health procurement contracts awarded.

Middle East and Africa

Turkey: Active pharmaceutical importing, with documented Ocrelizumab shipments.
Iraq: Government pharmaceutical procurement database listings.

Procurement Channels and Sourcing Strategies

API Procurement

For pharmaceutical companies and contract manufacturers seeking Ocrelizumab API, several sourcing channels exist:

GMP-Certified Manufacturers: API suppliers must meet global pharmacopeia standards (USP/EP/JP) and maintain GMP certification.
Regulatory Documentation: Qualified buyers can request Drug Master Files (DMF), Certificates of Analysis (COA), and Material Safety Data Sheets (MSDS).
Lead Times: API procurement typically requires 7 to 60 days, depending on batch size and production schedule.
Export Capabilities: Ocrelizumab injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America.

Finished Drug Product Procurement

Buyers of finished Ocrelizumab products (Ocrevus) typically engage through:

Manufacturer-Direct Channels: Roche/Genentech supplies through authorized distributors and specialty wholesalers.
Specialty Wholesalers: DSCSA-compliant US wholesalers provide full serial traceability.
Cross-Border Sourcing: Platforms facilitating named-patient imports for countries with limited local availability.
Public Tenders: Government procurement agencies issue requests for proposals and award contracts through formal bidding processes.

Key Considerations for Buyers

When sourcing Ocrelizumab, buyers should evaluate:

Regulatory Compliance: Ensure suppliers meet FDA, EMA, or relevant regional regulatory requirements.
Supply Chain Integrity: Verify DSCSA compliance for US-sourced products.
Pricing and Reimbursement: Ocrelizumab’s high price may limit accessibility in some regions; buyers should understand reimbursement mechanisms.
Biosimilar Options: As biosimilars enter the market, buyers gain additional sourcing options with potentially lower costs.

How to Identify and Connect with Ocrelizumab Buyers

Trade Data Platforms

Several platforms provide access to import-export data that can help identify Ocrelizumab buyers:

The Trade Vision: Offers buyer profiles with shipment data, HS codes, and trading partner information.
Pharmacompass: Provides API manufacturer and supplier directories.
Pharmatradz: Lists bulk manufacturers and suppliers with export capabilities.

Public Procurement Databases

Government procurement platforms offer transparency into public sector buying:

Zakupivli.pro (Ukraine): Lists Ocrelizumab tenders and awarded contracts.
Brazil Government Portal: Documents municipal and state-level pharmaceutical procurement.
Paraguay Contracting System: Records Ministry of Public Health procurements.

Industry Reports and Market Intelligence

Market research reports provide buyer segmentation and market sizing:

Global Ocrelizumab Market Reports: Cover manufacturers, regions, and application forecasts .
Anti-CD20 Monoclonal Antibodies Reports: Include Ocrelizumab within broader market analysis.
Competitive Landscape Analysis: Offer insights into market participants and strategic positioning.

Market Trends Shaping Ocrelizumab Procurement

Biosimilar Entry and Market Expansion

The anticipated entry of Ocrelizumab biosimilars will reshape the buyer landscape. Key developments include:

Teva-Polpharma Agreement: This global licensing deal grants Teva exclusive rights to commercialize both intravenous and subcutaneous formulations of an Ocrelizumab biosimilar.
Multiple Phase 3 Trials: Amgen, Biocad, and Sandoz are advancing Ocrelizumab biosimilars through clinical development.
Patent Cliff: The 2029 US patent expiration for Ocrevus is expected to trigger significant biosimilar market entry.

Subcutaneous Formulation Advancements

Roche secured FDA approval for Ocrevus Zunovo (subcutaneous formulation) in September 2024, addressing the IV-only inconvenience. This development expands the product portfolio available to buyers and may influence procurement decisions based on administration preferences.

Geographic Market Expansion

As MS diagnosis rates increase globally, particularly in emerging markets, new buyers are entering the Ocrelizumab procurement ecosystem. Countries like India, China, and Brazil represent growing markets with expanding healthcare infrastructure and pharmaceutical procurement capabilities.

Supply Chain Resilience

The pharmaceutical industry’s focus on supply chain resilience is influencing Ocrelizumab procurement strategies. Buyers increasingly prioritize:

Supplier Diversification: Reducing dependence on single sources.
Traceability: Ensuring full chain-of-custody documentation.
Regulatory Compliance: Meeting evolving standards for pharmaceutical sourcing.

Challenges and Considerations for Ocrelizumab Buyers

Pricing and Affordability

Despite its therapeutic advantages, Ocrelizumab’s high price may limit accessibility in countries with lower economic conditions. Buyers must navigate complex pricing, reimbursement, and procurement strategies to ensure patient access while managing healthcare budgets.

Regulatory Complexity

Ocrelizumab procurement involves navigating multiple regulatory frameworks:

FDA Approval: Required for US market access.
EMA Approval: Required for European market access.
Regional Approvals: Each country maintains its own regulatory requirements.

Supply Constraints

Periodic supply shortages can affect Ocrelizumab availability. Buyers should develop contingency plans and maintain relationships with multiple sourcing partners.

Quality Assurance

Ensuring product quality and authenticity is paramount. Buyers should:

Verify GMP Certification: Ensure manufacturers maintain WHO-GMP, EU-GMP, or USFDA certifications.
Request Regulatory Documentation: Obtain DMF, COA, and other quality documents.
Conduct Due Diligence: Verify supplier credentials and supply chain integrity.

Future Outlook: The Evolving Ocrelizumab Buyer Landscape

The Ocrelizumab market is poised for significant transformation over the coming years. Several factors will shape the future buyer landscape:

Market Growth and Expansion

With the global Ocrelizumab market projected to reach US$3.38 billion by 2032, the number and diversity of buyers will continue to expand. Emerging markets, in particular, will contribute to this growth as healthcare infrastructure develops and MS diagnosis rates increase.

Biosimilar Competition

The entry of Ocrelizumab biosimilars will introduce new suppliers and potentially lower costs, expanding the buyer base to include price-sensitive markets and healthcare systems. Buyers will gain additional sourcing options and negotiating leverage.

Technological Advancements

Advances in pharmaceutical manufacturing, supply chain management, and procurement technology will streamline Ocrelizumab sourcing. Digital platforms for pharmaceutical procurement will continue to evolve, making it easier for buyers to identify and connect with suppliers.

Regulatory Harmonization

Efforts toward regulatory harmonization across major markets may simplify cross-border Ocrelizumab procurement, benefiting both buyers and suppliers.

ROCHE FARMA PERU S A
ТОВАРИСТВО З ОБМЕЖЕНОЮ ВІДПОВІДАЛЬНІСТЮ САНАКЛІС 08322 УКРАЇНА КИЇВСЬКА ОБЛ БОРИСПІЛЬСЬКИЙ Р Н С ПРОЛІСКИ ВУЛ СО
PRODS ROCHE S A
PRODUCTOS ROCHE SA DE CV
ROCHE CHILE LIMITADA
ROCHE PAKISTAN LIMITED
PPD PHARMACEUTICAL DEVELOPMENT INDIA PRIVATE LIMIT
ROCHE PRODUCTS INDIA PRIVATE LIMITED
ROCHE MUSTAHZARLARI SANAYI ANONIM SIRKETI
GLOBAL MEDICAL LOGISTICS S A
CEFA CENTRAL FARMACEUTICA SOCIEDAD ANONIMA
RELIANCE LIFE SCIENCES PRIVATE LIMITED
CURATEQ BIOLOGICS PRIVATE LIMITED
DR REDDY S LABORATORIES LTD
NOVARTIS FARMACEUTICA SA DE CV
ТОВ ІМП ЛОГІСТИКА УКРАЇНА 02094 М КИЇВ ВУЛ ВІСКОЗНА 8
ТОВАРИСТВО З ОБМЕЖЕНОЮ ВІДПОВІДАЛЬНІСТЮ САНАКЛІС 08322 КИЇВСЬКА ОБЛ БОРИСПІЛЬСЬКИЙ Р Н С ПРОЛІСКИ ВУЛ СОБОРНА 18
OOO ASTOR ALLIANCE
ROCHE SERVICIOS SOCIEDAD ANONIMA
ТОВАРИСТВО З ОБМЕЖЕНОЮ ВІДПОВІДАЛЬНІСТЮ САНАКЛІС 08322 УКРАЇНА КИЇВСЬКА OБЛ БOРИСПІЛЬСЬКИЙ Р Н С ПРOЛІСКИ ВУЛ СO

Conclusion

The Ocrelizumab global buyers list encompasses a diverse ecosystem of pharmaceutical manufacturers, hospital systems, specialty pharmacies, government agencies, and private importers. As the market continues its robust growth trajectory—fueled by increasing MS diagnoses, expanding treatment access, and the anticipated entry of biosimilars—understanding this buyer landscape becomes increasingly important for stakeholders across the pharmaceutical supply chain.

For buyers seeking to source Ocrelizumab, success requires navigating complex regulatory requirements, maintaining supply chain integrity, and staying informed about market developments. For suppliers and manufacturers, understanding buyer categories, regional dynamics, and procurement channels is essential for effective market penetration and commercial success.

As the Ocrelizumab market evolves toward its projected US$3.38 billion valuation by 2032, the network of global buyers will continue to expand and diversify, creating new opportunities and challenges for all participants in this critical therapeutic segment.